Sanofi Pasteur signs R&D pact with UC San Diego for acne treatment - Pharmaceutical Business Review

Thank you for using! This service has been made possible by all our customers. In order to provide a sustainable, best of the breed RSS to Email experience, we've chosen to keep this as a paid subscription service. If you are satisfied with your free trial, please sign-up today. Subscriptions without a plan would soon be removed. Thank you!
PBR Staff Writer Published 21 September 2011

Sanofi-aventis' Sanofi Pasteur has signed a research and development pact with the University of California, San Diego (UC San Diego), US, for its experimental acne vaccine and treatment.

The deal includes a two-year research collaboration with Chun-Ming Huang and his associates at UC San Diego School of Medicine for further research and development.

Further, the financial terms of the agreement were not disclosed.

Sanofi Global Research & Development president Elias Zerhouni said this opportunity could provide an immunotherapeutic product with benefits and a novel mechanism of action to address an unmet medical need.

"This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease," Zerhouni said.

21 Sep, 2011

Manage subscription | Powered by

What's on Your Mind...

Powered by Blogger.